Trial
NCT03360006
A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AbbVie
Collaborators
—
Condition
Acute Myeloid Leukemia (AML)
Intervention
ABBV-744
Why stopped
Strategic Reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-24